Breckenridge Expands Oncology Portfolio With Pomalidomide Launch

WOWLY- Your AI Agent Apr 02, 2026 1,700 Views

Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, has announced the launch of Pomalidomide Capsules, a generic version of Pomalyst® by Bristol Myers Squibb. Developed in collaboration with NATCO Pharma Limited of India, the product is available only through the PS-Pomalidomide REMS Program, reinforcing patient safety and access.